AI Score

Unlock

Scholar Rock (SRRK)

AI Score

Unlock

32.81

-0.55 (-1.65%)

At close: Mar 28, 2025, 3:59 PM

32.61

-0.60%

After-hours: Mar 28, 2025, 06:19 PM EDT

-1.65% (1D)

Bid	30
Market Cap	3.11B
Revenue (ttm)	n/a
Net Income (ttm)	-233.56M
EPS (ttm)	-2.47
PE Ratio (ttm)	-13.28
Forward PE	-18.22
Analyst	Buy

Ask	38.18
Volume	697,695
Avg. Volume (20D)	964,311
Open	33.42
Previous Close	33.36
Day's Range	32.03 - 33.93
52-Week Range	6.76 - 46.98
Beta	0.60

About SRRK

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical tria...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 25, 2018

Employees 128

Stock Exchange NASDAQ

Ticker Symbol SRRK

Website https://scholarrock.com

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for SRRK stock is "Buy." The 12-month stock price forecast is $43.5, which is an increase of 32.58% from the latest price.

Stock Forecasts

Why Price Moved

4 months ago

+26.07%

Scholar Rock stock is trading higher after rival B... Unlock content with Pro Subscription

4 months ago

-5.29%

Scholar Rock Holding shares are trading lower after the company reported worse-than-expected Q3 EPS results.

News

4 days ago · businesswire.com

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders,...

1 week ago · benzinga.com

Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment

Scholar Rock Holding Corp. SRRK said on Sunday the company will present new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial at the 2025 Muscular Dystrophy Association (MDA) Clinical &...

1 week ago · businesswire.com

Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

2 weeks ago · businesswire.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometa...

1 month ago · seekingalpha.com

Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call Transcript

Scholar Rock Holding Corporation. (NASDAQ:SRRK ) Q4 2024 Earnings Conference Call February 27, 2025 8:15 AM ET Company Participants Jay Backstrom - President & CEO Ted Myles - COO & CFO Tracey Sacco -...

1 month ago · businesswire.com

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic dis...

1 month ago · seekingalpha.com

Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Apitegromab is being explored in the phase 2 pr...